Dr. Roy Rabinowitz is the CEO and co-founder of Kanso Diagnostics, a company focused on improving the patient-doctor experience by delivering molecular diagnostics to the point of need. With three patents submitted and $1.8M in secured funding, Kanso’s platform enables detection of pathogens and antimicrobial resistance testing, even in home settings. Kanso is backed by the IIA, Peregrine Ventures and industry giants such as Becton Dickinson and Bristol Myers Squibb. Dr. Rabinowitz holds a Ph.D. from Tel Aviv University, where he investigated the specificity and safety of the CRISPR gene-editing system. During his Ph.D., he authored six peer-reviewed papers and filed three patents. His research was recognized with a number of awards and scholarships, including the prestigious Dan David Prize scholarship.